Drug information update: Agomelatine

Psychiatrist

Volumn 37, Issue 11, 2013, Pages 356-358

  Whiting, Daniel ^a   Cowen, Philip J ^a  

^a WARNEFORD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGOMELATINE; ANTIDEPRESSANT AGENT; CIPROFLOXACIN; ESTROGEN; FLUOXETINE; FLUVOXAMINE; MELATONIN RECEPTOR; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; PLACEBO; PROPRANOLOL; SEROTONIN 2C RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ARTICLE; BACKACHE; BEDTIME DOSAGE; BIPOLAR DEPRESSION; CIRCADIAN RHYTHM; CONSTIPATION; DEPRESSION; DIARRHEA; DIZZINESS; DROWSINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG INFORMATION; DRUG MECHANISM; DRUG METABOLISM; DRUG RECEPTOR BINDING; FATIGUE; HEADACHE; HEPATITIS; HUMAN; INSOMNIA; JAUNDICE; LIVER FUNCTION TEST; MAJOR DEPRESSION; NAUSEA; SEXUAL DYSFUNCTION; SIDE EFFECT; SWEATING; UNITED KINGDOM;

EID: 84887243534     PISSN: 17583209     EISSN: 17583217     Source Type: Journal    
DOI: 10.1192/pb.bp.113.043505     Document Type: Article

References (21)

1. Boivin DB. Influence of sleep-wake and circadian rhythm disturbances in psychiatric disorders. J Psychiatry Neurosci 2000; 25: 446-58.
2. Germain A, Kupfer DJ. Circadian rhythm disturbance in depression. Human Psychopharmacol 2008; 23: 571-85.
3. Pandi-Perumal SR, Trakht I, Spence DW, Srinivasan V, Dagan Y, Cardinali DP. The roles of melatonin and light in the pathophysiology and treatment of circadian rhythm sleep disorders. Nat Clin Pract Neurol 2008; 4: 436-47.
4. Millan MJ, Gobert A, Lejeune F, Dekeyne A, Newman-Tancredi A, Pasteau V, et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 2003; 306: 954-64.
5. Pandi-Perumal SR, Trakht I, Srinivasan V, Spence DW, Masetroni GJM, Zisapel N, et al. Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways. Prog Neurobiol 2008; 85: 335-53.
6. San L, Arranz B. Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system. Eur Psychiatry 2008; 23: 396-402.
7. Tardito D, Molteni R, Popoli M, Racagni G. Synergistic mechanisms involved in the antidepressant effects of agomelatine. Eur Neuropsychopharmacol 2012;22 (suppl 3): S482-6.
8. Molteni R, Calabrese F, Pisoni S, Gabriel C, Racagni G, Riva MA. Synergistic mechanisms in the modulation of the neurotrophin BDNF in the rat prefrontal cortex following acute agomelatine administration. World J Biol Psychiatry 2010; 11: 148-53.
9. Sen S, Duman R, Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry 2008; 64: 527-32.
10. Sharpley AL, Rawlings NB, Brain S, McTavish SFB, Cowen PJ. Does agomelatine block 5-HT2c receptors in humans? Psychopharmacology 2011; 213: 653-5.
11. Krauchi K, Cajochen C, Mori D, Graw P, Wirz-Justice A. Early evening melatonin and S-20098 advance circadian phase and nocturnal regulation of core body temperature. Am J Physiol 1997; 272: R1178-88.
12. Leproult G, Van Onderbergen A, L'hermite-Baleriaux M, Van Cauter E, Copinschi G. Phase-shifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men. Clin Endocrinol 2005; 63: 298-304.
13. British Medical Association, Royal Pharmaceutical Society. British National Formulary (64th edn, September 2012). BMJ Group & Pharmaceutical Press, 2012.
14. Hickie IB, Rogers N. Novel melatonin-based therapies: potential advances in the treatment of major depression. Lancet 2011; 378: 621-31.
15. Singh SP, Singh V, Kar N. Efficacy of agomelatine in major depressive disorder: meta-analysis and appraisal. Int J Neuropsychopharmacol 2012; 15: 417-28.
16. Barbui C, Cipriani A. Agomelatine and the brave old world of narrativebased medicine. Evid Based Ment Health 2012; 15: 2-3.
17. Rihmer Z, Dome P, Baldwin DS, Gonda X. Psychiatry should not become hostage to placebo: an alternative interpretation of antidepressantplacebo differences in the treatment response in depression. Eur Neuropsychopharmacol 2012; 22: 782-6.
18. Zajecka J, Schatzberg A, Stahl S, Caputo A, Post A. Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicentre, randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol 2010; 30: 135-44.
19. Montejo A, Majadas S, Rizvi SJ, Kennedy SH. The effects of agomelatine on sexual function in depressed patients and healthy volunteers. Hum Psychopharmacol 2011; 26: 537-42.
20. Sparshatt A, McAllister-Williams RH, Baldwin DS, Haddad PM, Bazire S, Weston S, et al. A naturalistic evaluation and audit database of agomelatine: clinical outcome at 12 weeks. Acta Psychiatr Scand 2013; 128: 203-11.
21. Lewy AJ. Circadian misalignment in mood disturbances. Curr Psychiatry Rep 2009; 11: 459-65.